Previous studies showed that as a transcriptional inducer, EZH2 functions independently (not as part of the PRC2 complex) in prostate cancer, breast cancer, intestinal cancer and natural killer/T-cell lymphoma (NKTL). This evidence concerns the gene EZH2 and prostate cancer.